Sara A. Hurvitz, MD, discussed targeted therapy advancements, the rise of trastuzumab biosimilars, and the future of HER2-positive breast cancer treatment.
Original Article: Hurvitz Highlights Advances in HER2+ Breast Cancer Treatment